protocolSection identificationModule nctId: NCT06347120, orgStudyIdInfo id: PI2024_843_0011, briefTitle: Place of Nasogastric Tube in Uncomplicated Adhesive Small Bowel Obstruction, acronym: BOWNTI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire, Amiens, class: OTHER, collaborators name: Centre Hospitalier de Beauvais, collaborators name: CHU de Rouen - Accueil, collaborators name: Hospital Avicenne, collaborators name: Centre Hospitalier Universitaire Dijon, collaborators name: University Hospital, Limoges, collaborators name: Saint Antoine University Hospital, collaborators name: Centre Hospitalier Universitaire de Besancon, collaborators name: Hôpital Cochin, collaborators name: University Hospital, Toulouse, collaborators name: CH Abbeville, collaborators name: University Hospital, Angers, descriptionModule briefSummary: Acute adhesive Small Bowel Obstruction (ASBO) is a public health issue: this is the 3rd cause of hospitalization in Digestive Surgery Departments, 20-30% of patients will be operated, the mortality rate per episode is 3%, the duration of hospitalization is 8 days (up to 16 if resection), and it is associated with a tremendous health care expenses.The working group on ASBO of the World Society of Emergency Surgery suggested two distinct approaches for the management of acute ASBO: non-operative management (NOM) which concerning around 85% of patients and operative management (OM) :* OM: if there is clinical signs of strangulation, peritonitis, bowel ischemia, or if IV CT Scan shows sign of ischemia, strangulation, peritonitis, or if the occlusion persists for more than 72 hours;* NOM in all other cases, including nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.NGT is an old concept first describe for treatment of ASBO based on several studies made on the dog where he proved efficacy of NGT by aspirating gas in the stomach favorising venous decompression and survival of patients. Since, NGT became one of the pillars of NOM.However NGT is quite bad tolerated by patients (ranked the most painful hospital procedure), some of them refuse it, others put off after the beginning of the treatment and one of the most frequent complications of NGT is pneumonia, which is quite surprising when the first argument for its insertion is to avoid inhalation pneumonia.Four specific retrospectives studies showed that absence of NGT is possible in 20 to 80% of included patients and was associated with a decrease: in transit recovery time; in complications rate (including rates of pneumonia); in length of stay (LOS); without an increased risk of surgery or resection. 20-87% (a total of 922 patients) were managed successfully conservatively without NGT with a reduction LOS of 2-6 days compared with NGT. But none of this series focused on the patient relief as an endpoint. A retrospective critical analysis of our own management (January - December 2019, n=96) found that: only 17% of patients had a NGT during the IV CTscan, the presence of the NGT did not influence neither gastric volume nor the rate of full stomach, and gastric volume did not influence patient management.To summarize, the investigators therefore know that the insertion of a NGT is painful, does not relieve all patients, and has an unquantified therapeutic effect on the evolution of ASBO. That is why it is pertinent, in 2023, to question the useless of NGT in the treatment of ASBO, in selected patients. This study would be the first randomized controlled trial to focus on the absence of NGT for the NOM of patients with ASBO. The results of this study could lead to a change in the surgical practice. The absence of NGT in ASBO management appears to be an innovative practice, in rupture with the current practice. This is a part of the simplification of patients'care suffering from ASBO., conditionsModule conditions: Small Bowel Obstruction Adhesion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 504, type: ESTIMATED, armsInterventionsModule interventions name: nasogastric tube, interventions name: NOM without NGT insertion, outcomesModule primaryOutcomes measure: Decrease of complication rate in patient without NGT group compared to control group, secondaryOutcomes measure: aspiration pneumonia rate in both patient groups, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Amiens Universitary Hospital, city: Amiens, country: France, contacts name: jean marc Regimbeau, Pr, role: CONTACT, phone: +33 3 22 08 89 05, email: regimbeau.jean-marc@chu-amiens.fr, contacts name: charles sabbagh, Pr, role: SUB_INVESTIGATOR, contacts name: Aiham Ghazali, Pr, role: SUB_INVESTIGATOR, contacts name: Thierry Yzet, Pr, role: SUB_INVESTIGATOR, contacts name: François Mauvais, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Lilian Schwarz, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Christophe Tresallet, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Pablo Ortega deballon, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Muriel Mathonnet, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Jérémie Lefevre, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Zaher Lakkis, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: David Fuks, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Fabrice Muscari, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Corina Iederan, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Aurelien Venara, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 49.9, lon: 2.3, hasResults: False